Prophylactic and curative effects of purslane on bile duct ligation-induced hepatic fibrosis in albino rats
Journal Title: Annals of Hepatology - Year 2011, Vol 10, Issue 3
Abstract
Introduction. Hepatic fibrosis is a common pathological process of chronic liver injury. Oxidative stress and inflammation may have prognostic value in disease progression. Objective. To examine the implication of both aforementioned factors in hepatic fibrosis progression and whether, the antioxidant effect of various biological active constituents such as phenolic, flavonoids and fatty acids of purslane hydro-ethanolic extract can represent a potential target for therapy. Methods. Purslane exhibited a considerable antioxidant potential in DPPH assay compared to α-tocopherol. Consequently, the current study was designed to examine the prophylactic and curative effects of purslane extract on bile duct ligation (BDL)-induced liver fibrosis in rats in comparison with silymarin as a reference hepatoprotective agent. Purslane (400 mg/kg/day) or silymarin (50 mg/kg/day) were administered orally for 4 weeks, immediately after surgery in order to evaluate the prophylactic effect and for 3 weeks starting 3 weeks after BDL in order to evaluate the curative effect. BDL significantly increased liver enzymes, total bilirubin (TB) and tumor necrosis factor-alpha (TNF-α) in serum along with malondialdehyde (MDA) in liver tissues. Results. Significant decrease in hepatic antioxidant defense system was noted in BDL-rats. Conversely, administration of purslane reversed all these biochemical parameters which were previously induced by BDL. Considerably, purslane effect was more pronounced in the prophylactic study than that in the curative one. Conclusion. The present work suggested that purslane had prophylactic and curative value on cholestasis-induced liver fibrosis through inhibition of oxidative stress, decreasing the expression of profibrogenic cytokines, collagenolytic activity and activation of hepatic stellate cells.Financial support from National Organization for Drug Control and Research, Giza.
Authors and Affiliations
Ehsan Khedre Mohammed Hassan, Mostafa M. Said, Sousou Ali
Keywords
Related Articles
- EP ID EP78051
- DOI -
- Views 126
- Downloads 0
Chronic hepatitis C treatment in näive patients
Hepatitis C (HCV) is a major public health problem worldwide and it is considered that there are about 180 millions of infected people. The natural history of hepatitis C shows that, of those individuals affected by a pr...
Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis
Lipoprotein X (LpX) is an abnormal lipoprotein associated with cholestasis. It is a significant cause of severe hypercholesterolemia and should always be considered in patients with cholestatic liver disease. This case h...
[b][/b]
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy
[b]Introduction[/b]. Complete suppression of viral replication is crucial in chronic HCV treatment in order to prevent relapse and resistance development. We wanted to find out which factors influence the period from bei...
Long-delayed gross hematuria due to portal hypertension in an alcoholic cirrhotic patient with ileal conduit urinary diversion
Bleeding varices at the stomal site is an uncommon complication of ileal conduit urinary diversion in patients with portal hypertension. We describe a case with the longest delay reported in the literature, involving the...